UPDATE 2-Roche CFO says Genentech debt talks on track

(Adds comments, background, byline)

By Deena Beasley

SAN FRANCISCO, Jan 12 (Reuters) - Roche Holding AG's_(ROG.VX) efforts to secure financing for its proposed takeover of Genentech Inc DNA.N are "absolutely on track," the Switzerland-based company's chief financial officer said on Monday.

CFO Erich Hunziker acknowledged that the deal, announced in July, "has started in a very complex environment," but noted that "after six months everything from our perspective is on track." Hunziker made the remarks at a JPMorgan healthcare conference.

He said Roche remains "fully committed" to the Genentech transaction.

Earlier on Monday, the company affirmed its dividend policy, dismissing talk that it might sacrifice payouts to help fund a sweetened offer for the 44 percent of the U.S. biotech giant it does not already own.

Roche shares slid 3.4 percent on worries over a Financial Times report late on Friday that the company was ready to scrap its dividend in order to boost its offer to Genentech shareholders.

Hunziker declined to comment on the report, which said Roche was preparing to offer $95 per share after Genentech rejected the $89-per-share offer made in July.

The CFO also said Roche expected to rely on its eight core banks for loans to complete the Genentech deal and has been preparing to move into a net debt position.